Desafiar o extremo: Expedição Kahuna à Patagónia patrocinada pela Deriv e o seu impacto na ciência climática

Recolha de amostras de neve para investigação
Dois exploradores recolhem amostras de neve no âmbito da expedição Kahuna.
Dois exploradores recolhem amostras de neve
  • O programa de patrocínio de RSE da Deriv apoia a equipa Kahuna na recolha de dados ambientais cruciais e na melhoria da compreensão global das alterações climáticas.
  • Em parceria com a OSER e a Cheer Up, a expedição ambiental visa sensibilizar e educar jovens doentes e estudantes.

CYBERJAYA, Malásia, May 16, 2024 (GLOBE NEWSWIRE) — À medida que a Deriv se prepara para celebrar 25 anos de inovação e responsabilidade, assinala com orgulho este momento importante com uma série de novas iniciativas que terão impacto em 2024 e no futuro. O patrocínio à Kahuna apoia a investigação científica e os projetos comunitários que proporcionam valor educativo e inspiram ações positivas para a proteção do ambiente.

A Deriv patrocinou recentemente a equipa Kahuna numa expedição de investigação ambiental na Patagónia. A expedição ambiental tinha como objetivo investigar a presença de microplásticos e carbono negro na neve. Estas substâncias são indicadores críticos de poluição ambiental que contribuem para as alterações climáticas.

A equipa estabeleceu uma parceria com o Instituto Argentino de Nivologia, Glaciologia e Ciências Ambientais e procurou envolver e interagir com a comunidade através de colaborações com as organizações de caridade OSER e CheerUp (afiliadas ao CentraleSupelec).

A equipa Kahuna a caminhar com as suas mochilas pesadas

Os caminhantes com as suas mochilas

Seema Hallon, Responsável pelos Recursos Humanos da Deriv, partilha: “O 25º aniversário representa uma oportunidade para a Deriv renovar o seu compromisso com os valores que consideramos fundamentais enquanto organização. Direcionar os nossos esforços de RSE para projetos significativos, como a expedição Kahuna, é a nossa forma de contribuir para a construção de um futuro sustentável para o planeta e as comunidades.”

A expedição teve inicio em meados de janeiro em Puerto Murta, no Chile, com uma equipa constituída por Baptistin Coutance, Robin Villard, Thomas Jarrey, Vincent Lavrov e Yvan Lazard.

A rota levou-os a atravessar o Lago General Carrera, através do Rio Baker até aos fiordes do Pacífico, ao longo do Campo de Hielo Continental, ascendendo ao Vulcão Lautaro e o Cerro Francisco Moreno, onde as más condições climatéricas levaram ao fim prematuro da viagem.

Robin Villard partilha: “A expedição foi um sucesso. As amostras recolhidas estão em bom estado e a sua análise está prevista para maio e julho. No final do verão, deveremos ter resultados sobre a presença de microplásticos no campo de gelo abaixo. Este feito representa um enorme sucesso.

A nossa investigação científica centrou-se na recolha de amostras de neve para análise, com o intuito de avaliar os níveis de microplásticos presentes. Simplificando, iremos examinar as amostras ao microscópio no laboratório para determinar a possível presença de uma poluição significativa de microplásticos na neve.”

Resultados da expedição:

  • Impacto da investigação: A equipa Kahuna recolheu e analisou com sucesso amostras da região, fornecendo dados valiosos para os estudos climáticos em curso.
  • Impacto na comunidade: Através de atualizações em tempo real e de apresentações subsequentes, a expedição ambiental proporcionará experiências educativas e motivacionais a jovens com cancro e a estudantes desfavorecidos quando o seu documentário estiver concluído.

A expedição enfrentou desafios, nomeadamente condições meteorológicas adversas e terreno perigoso, mas conseguiu cumprir eficazmente os seus objetivos de investigação.

Os caminhantes com as suas mochilas Deriv

Saiba mais sobre a expedição Kahuna.

Sobre a Deriv

Ao longo de 25 anos, a Deriv manteve um compromisso firme de tornar a negociação online acessível a qualquer pessoa, em qualquer lugar. Com a confiança de mais de 2,5 milhões de traders em todo o mundo, a empresa oferece uma ampla variedade de tipos de negociação e disponibiliza mais de 200 ativos em mercados populares nas suas plataformas de negociação premiadas e intuitivas. Com uma força de trabalho de mais de 1.300 pessoas em todo o mundo, a Deriv tem cultivado um ambiente que celebra conquistas, incentiva o crescimento profissional e promove o desenvolvimento de talentos, o que é refletido na sua acreditação Platinum pela Investors in People.

CONTACTO DE IMPRENSA
pr@deriv.com

Fotos deste comunicado podem ser encontradas em
https://www.globenewswire.com/NewsRoom/AttachmentNg/ef2965d5-c8b1-4871-bacc-0269b2f6db03/pt
https://www.globenewswire.com/NewsRoom/AttachmentNg/566a2521-6397-441c-9785-dde4576f6cb7/pt

GlobeNewswire Distribution ID 9118271

Workvivo by Zoom is named preferred migration partner for Workplace from Meta

Meta is discontinuing Workplace and will partner with Workvivo to assist with customer transitions.

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Today, Workvivo by Zoom was named Meta’s only preferred migration partner for its customers as it retires Workplace from Meta.

Meta is discontinuing Workplace from Meta – its employee engagement platform. To assist with customer transitions, Meta will partner with Workvivo as its only preferred migration partner.

Workplace from Meta and Workvivo plan to provide migration tools for customers migrating to Workvivo and Workvivo will also offer additional implementation services at no further cost to support customers’ transition.

Workplace from Meta customers can find more information about migrating to Workvivo here.

John Goulding, CEO and founder of Workvivo, said: “We know that the news today may be disruptive for Workplace from Meta customers, but we’re so excited about the opportunity to support and help them. Meta has made a huge impact in this market, and we believe that Workvivo is the natural choice for Workplace from Meta customers to transition their employee experience platform.

“It’s our top priority to support customers through this transition, and our team is working to make this process as frictionless as possible. We put our customers first, and this will be no different for the Workplace from Meta customers. We are excited to welcome Workplace from Meta customers into our incredible customer community and see the amazing things they can do with Workvivo.”

Eric S. Yuan, CEO and founder of Zoom said: “Since Workvivo joined the Zoom family, we’ve seen how powerful this platform is at engaging workforces and bringing culture to life – especially for frontline employees who may not have a desk or even an email address. Workvivo has seen momentous growth as organizations around the world are increasingly prioritizing the employee experience. We are excited to support Workplace from Meta’s customers and help them reach their goals of reaching and engaging employees – whether they’re desk or frontline workers.”

Workvivo by Zoom is the employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work.

Acquired by Zoom in 2023, Workvivo extends the Zoom Workplace platform to offer its customers new ways to keep employees informed, engaged, and connected. Workvivo is working with some of the world’s best-known brands to help them boost employee engagement and bring their culture to life digitally, including Dollar General, the Virgin Group, Bupa, Ryanair, Lululemon and Amazon.

About Workvivo by Zoom

Workvivo is an employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work. The platform unifies employee communications, engagement, intranet, and measurement features into one modern employee app that captures the heartbeat of the organization and brings its culture to life.

Founded in 2017, Workvivo has seen momentous growth, which led to its acquisition by Zoom in 2023. Workvivo powers the employee experience at companies all over the world across all industries, including Amazon, Motherson, White Castle, Bupa and Ryanair. Workvivo regularly tops software review sites, including Gartner Digital, with a #1 spot on G2 for internal communications, intranet and engagement tool categories. For more information, visit www.workvivo.com.

Public Relations
Eleanor O’Mahony
eleanor.omahony@zoom.us

GlobeNewswire Distribution ID 9117415

En pleine transformation stratégique, le King Faisal Specialist Hospital and Research Centre accueille un nouveau directeur général adjoint

RIYAD, Arabie saoudite, 14 mai 2024 (GLOBE NEWSWIRE) — L’hôpital spécialisé et centre de recherche King Faisal, ou KFSH&RC pour King Faisal Specialist Hospital and Research Centre a récemment accueilli le Dr Björn Zoéga en tant que directeur général adjoint. Cette nomination souligne son engagement en faveur de la promotion et du maintien de l’excellence en matière de santé. Le Dr Zoéga, réputé pour sa vaste expérience en gestion et sa maîtrise des politiques de la santé, rejoint une équipe dédiée à l’heure où l’hôpital continue de piloter des initiatives stratégiques clés.

Le KFSH&RC, leader de la recherche médicale et des services cliniques, continue d’attirer des ressources expertes à l’échelle mondiale pour renforcer sa mission d’excellence en matière de santé. L’arrivée du Dr Zoéga fait avancer la stratégie de transformation numérique de l’hôpital, conçue pour doper son efficacité opérationnelle et améliorer les soins prodigués aux patients. Son expertise dans la promotion de collaborations internationales, comme en témoigne son ancien rôle de président de l’Alliance des hôpitaux universitaires européens (ou « EUHA » pour European University Hospital Alliance) et sa participation à des initiatives telles que JOIN4ATMP, visant à promouvoir l’accès à des thérapies innovantes, concourent à un meilleur alignement des services du KFSH&RC sur les tendances mondiales en matière de santé.

Les projets clés de l’hôpital prévoient le déploiement de technologies numériques avancées pour standardiser les mécanismes propres aux soins prodigués aux patients, l’adoption de nouveaux modèles de soins et la modernisation de ses installations. Ces efforts stratégiques visent à améliorer l’accès aux services médicaux et à induire une meilleure communication à leur propos, et traduisent l’engagement du KFSH&RC envers l’établissement de nouvelles normes en matière de santé.

Les précédentes contributions du Dr Zoéga à l’hôpital universitaire Karolinska, placé au deuxième rang européen et au septième rang mondial du classement 2024 des meilleurs hôpitaux du monde établi par Newsweek, ont joué en faveur d’une culture d’apprentissage continu et de collaboration entre les professionnels de santé. Elles répondent ainsi parfaitement aux objectifs du KFSH&RC. Son rôle dans la promotion de programmes comme EUCARE et sa participation au développement des échanges intra Europe d’infirmières en soins intensifs en période de crise a considérablement renforcé le développement du personnel et appuyé l’objectif de son précédent hôpital d’attirer les meilleurs talents ; un principe reflété dans le parcours de transformation du KFSH&RC. Maintenant que le Dr Zoéga prend part au leadership du KFSH&RC, l’établissement s’apprête à renforcer son rôle d’acteur clé dans le façonnage de la santé de demain en Arabie saoudite.

À propos du King Faisal Specialist Hospital and Research Centre :

Le King Faisal Specialist Hospital & Research Centre fait partie des leaders mondiaux en matière de soins de santé spécialisés, et d’innovation, servant de centre de formation et de recherche médicale avancée. Grâce à des partenariats stratégiques avec d’éminents établissements locaux, régionaux et internationaux, l’hôpital se consacre à l’avancement des technologies médicales et à l’élévation des normes de soins de santé dans le monde entier.

L’hôpital a conforté sa position de leader du secteur de la santé en Arabie saoudite et au Moyen-Orient, en se voyant décerner, pour la deuxième année consécutive, le titre de marque de santé la plus valorisée. Il se classe 9e du royaume et 28e au Moyen-Orient. L’hôpital se distingue en étant le seul hôpital du monde à figurer au top 10 des marques de son pays, comme le soulignent deux rapports de « Brand Finance » consacrés aux 50 meilleures marques d’Arabie saoudite et aux 150 meilleures marques du Moyen-Orient en 2024.

En raison des programmes de transformation et du projet royal « Saudi Vision 2030 » initié par Son Altesse Royale le Prince Héritier et Premier Ministre — que Dieu le préserve — pour renforcer le leadership du royaume dans le secteur de la santé mondiale, le KFSH&RC est devenu un centre médical universitaire de première importance dans la région MENA. En 2024, il s’est classé au 20e rang mondial pour la deuxième année consécutive selon « Brand Finance », et s’est également distingué parmi les 250 meilleurs hôpitaux du monde selon le magazine américain « Newsweek » cette même année.

Pour tout complément d’information, veuillez contacter :

M. Essam AlZahrani, Responsable des affaires médiatiques, 0555254429

M. Abdullah Alown, Coordinateur médias, 0556294232

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605-9a75-41cb-8947-81c858209621

GlobeNewswire Distribution ID 9117305

King Faisal Specialist Hospital and Research Centre Dá as Boas-Vindas ao Novo CEO Interino Durante Suas Transformações Estratégicas

RIADE, Arábia Saudita, May 14, 2024 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital and Research Centre (KFSH&RC) nomeou recentemente o Dr. Björn Zoéga como CEO Interino, confirmando o seu empenho em promover e incentivar a excelência no cuidado da saúde. O Dr. Zoéga, conhecido por sua vasta experiência em gestão e políticas de saúde, se une a uma equipe dedicada em um momento em que o hospital continua a impulsionar iniciativas estratégicas importantes.

O KFSH&RC, líder em pesquisa médica e serviços clínicos, continua a atrair experiência global para reforçar sua visão de excelência em saúde. Com o envolvimento do Dr. Zoéga, o hospital dá seguimento à sua estratégia de transformação digital que visa aprimorar a eficiência operacional e aperfeiçoar o atendimento ao paciente. Sua experiência na promoção de colaborações internacionais, evidenciada no seu antigo cargo de presidente da European University Hospital Alliance (EUHA) e com as iniciativas como a Join4ATMP, que visa promover o acesso a terapias inovadoras, alinha ainda mais os serviços do KFSH&RC às tendências globais de saúde.

Os principais projetos do KFSH&RC incluem a implantação de tecnologias digitais avançadas para agilizar o processo de atendimento ao paciente, adoção de modelos de atendimento inovadores e atualização das instalações. Esses esforços estratégicos visam aumentar o acesso aos serviços médicos e facilitar uma melhor comunicação, refletindo a dedicação do KFSH&RC em estabelecer novos padrões de saúde.

As contribuições anteriores do Dr. Zoéga no Karolinska University Hospital, que é o segundo melhor da Europa e o sétimo do mundo de acordo com o 2024 World’s Best Hospitals da revista Newsweek, onde ele cultivou uma cultura de aprendizagem contínua e colaboração entre profissionais de saúde, alinham-se bem com os objetivos do KFSH&RC. O seu papel na promoção de programas como o EUCARE e na facilitação do intercâmbio de enfermeiros de cuidados intensivos em toda a Europa durante crises melhorou significativamente o desenvolvimento do pessoal e apoiou o objetivo do seu hospital anterior de atrair os melhores talentos – um princípio espelhado na jornada de transformação do KFSH&RC. Com o Dr. Zoéga contribuindo para a liderança, o KFSH&RC está pronto para promover seu papel como ator fundamental na formação do futuro dos cuidados de saúde na Arábia Saudita.

Sobre o King Faisal Specialist Hospital and Research Centre :

O King Faisal Specialist Hospital & Research Centre é dos líderes globais de prestação de cuidados de saúde especializados, condução de inovação, e um hubs avançado de pesquisa e educação médica. Por meio de parcerias estratégicas com proeminentes instituições locais, regionais e internacionais, o hospital se dedica ao avanço de tecnologias médicas e elevação dos padrões de cuidado da saúde em todo o mundo.

O hospital conquistou sua posição como marca líder no setor de saúde em todo o Reino e Oriente Médio, marcando seu segundo ano consecutivo como a marca de saúde mais valiosa. Ele ocupa o 9º lugar no Reino e o 28º no Oriente Médio. O hospital se distingue como o único hospital do mundo a ser listado entre as 10 principais marcas do seu país, de acordo com dois relatórios da “Brand Finance” sobre as 50 marcas mais valiosas da Arábia Saudita e as 150 marcas mais valiosas do Oriente Médio em 2024.

Devido aos programas de transformação e à Vision 2030 do Reino, lançados por Sua Alteza Real o Príncipe Herdeiro e pelo Primeiro-Ministro – que Deus o proteja – para aumentar a liderança do Reino no setor global de saúde, o KFSH&RC surgiu como um dos principais Centros Médicos Acadêmicos do Oriente Médio e da África. Ele permaneceu em 20º lugar no mundo pelo segundo ano consecutivo em 2024, de acordo com o “Brand Finance”. Além disso, ele foi classificado entre os melhores hospitais do mundo em 2024 pela revista americana “Newsweek”.

Para mais informações, contate:

Sr. Essam AlZahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Alown, Editor Sênior de Mídia, 0556294232

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605-9a75-41cb-8947-81c858209621

GlobeNewswire Distribution ID 9117305

MedSource Labs Announces Innovation in Safety, Accuracy and Functionality of IV Catheters

MedSource Labs Unveils ClearSafe Comfort® and TrueSafe Comfort® Blood Control Safety IV Catheters to protect medical staff and patients

[Minneapolis, Minnesota, Chanhassen], May 14, 2024 (GLOBE NEWSWIRE) — MedSource Labs moves the needle in the peripheral safety IV market with the announcement of ClearSafe Comfort and TrueSafe Comfort Blood Control IV Catheters with groundbreaking active blood control check valve technology.

ClearSafe Comfort and TrueSafe Comfort Blood Control IV catheters provide significant benefits over other IV catheters.

  1. Safety: A new blood control device to significantly reduce the risk of exposure to bloodborne pathogens to the caregiver and patient.
  2. Precision: A translucent flashback chamber confirms vessel entry and ensures accuracy.
  3. Front-line functionality: The ergonomic design and non-slip grip ensure easy handling for healthcare workers.

 

“Healthcare professionals subject themselves to the risks associated with needlestick injuries and exposure to bloodborne pathogens every time they access a vein,” said Dave Kunelius, President at MedSource Labs. “ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters have been engineered to minimize these risks, allowing medical staff to better serve their patients without distraction or worry.”

These devices conform to the U.S. Needlestick Safety and Prevention Act.

MedSource Labs is a leading medical product developer and supplier specializing in high-quality products and innovative medical product development. The ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters are part of MedSource Labs’ high-performing IV catheter lines focused on caring for the caregiver. See the TrueSafe Animations and ClearSafe Animations for a detailed view.

“Quality has always been a key component of our IV catheter products, and the ClearSafe Comfort and TrueSafe Comfort blood control products raise the bar for medical staff safety and patient care,” said Kunelius.

MedSource Labs is ISO 13485:2016 certified for quality management in medical device manufacturing, registered with the FDA, and the blood control catheters are 510(k) Cleared Products.

ABOUT MEDSOURCE LABS

MedSource Labs is a leading provider of quality medical products, specializing in high-quality products, equipment and innovative class II medical product development. For over two decades, MedSource Labs has been a trusted provider of quality medical products at a superb value. Recently, MedSource Labs has expanded into new markets and grown its international services and offerings, including a focus on the EMERGE product imagine/design/build process.

Attachment

Jeremy Belloit
MedSource Labs
(952) 472-0131
jbelloit@medsourcelabs.com

GlobeNewswire Distribution ID 9116905

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations
King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

RIYADH, Saudi Arabia, May 13, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) has recently welcomed Dr. Björn Zoéga as its Deputy CEO, an appointment that underscores its commitment to promoting and fostering healthcare excellence. Dr. Zoéga, renowned for his extensive experience in healthcare management and policy, joins a dedicated team as the hospital continues to drive key strategic initiatives.

KFSH&RC, a leader in medical research and clinical services, continues to attract global expertise to bolster its vision of healthcare excellence. With Dr. Zoéga’s involvement, the hospital is advancing a digital transformation strategy designed to improve operational efficiency and enhance patient care. His expertise in fostering international collaborations, evidenced by his former role as president of the European University Hospital Alliance (EUHA) and through initiatives like JOIN4ATMP aimed at advancing access to innovative therapies, further aligns KFSH&RC’s services with global healthcare trends.

Key projects at KFSH&RC include the deployment of advanced digital technologies to streamline the patient care process, the adoption of innovative care models, and the upgrading of facility amenities. These strategic efforts aim to improve access to medical services and facilitate better communication, reflecting KFSH&RC’s dedication to setting new standards in healthcare.

Dr. Zoéga’s previous contributions at Karolinska University Hospital, which is ranked the second best in Europe and seventh globally by Newsweek’s 2024 World’s Best Hospitals, where he nurtured a culture of continuous learning and collaboration among healthcare professionals, align well with KFSH&RC’s objectives. His role in fostering programs like EUCARE and facilitating the Europe-wide exchange of intensive care nurses during crises has significantly enhanced staff development and supported his previous hospital’s goal of attracting top talent—a principle mirrored in KFSH&RC’s transformation journey. With Dr. Zoéga contributing to leadership, KFSH&RC is poised to further its role as a pivotal player in shaping the future of healthcare in Saudi Arabia.

About King Faisal Specialist Hospital and Research Centre:

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating healthcare standards worldwide.

The hospital has secured its position as the leading brand in the healthcare sector across the Kingdom and the Middle East, marking its second consecutive year as the most valuable healthcare brand. It ranks 9th within the Kingdom and 28th in the Middle East. The hospital distinguishes itself as the sole hospital globally to break into the top 10 brands in its country, as highlighted in two reports by “Brand Finance” on the 50 most valuable brands in Saudi Arabia and the 150 most valuable brands in the Middle East in 2024.

Due to the transformation programs and the Kingdom’s Vision 2030, launched by His Royal Highness the Crown Prince and Prime Minister – may God protect him – to enhance the Kingdom’s leadership in the global healthcare sector, KFSH&RC has emerged as a leading Academic Medical Centre in the Middle East and Africa. It maintained its 20th rank globally for the second consecutive year in 2024, according to “Brand Finance.” Additionally, it has been ranked among the top 250 hospitals globally in 2024 by the American magazine “Newsweek.”

For further information, please contact:

Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Alown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605-9a75-41cb-8947-81c858209621

GlobeNewswire Distribution ID 9116335

Impulse Dynamics Surpasses 10,000 Patients Benefiting From CCM® Therapy for Heart Failure

Milestone Highlights Transformative Symptom Management for Patients Living with Heart Failure

Marlton, NJ, May 13, 2024 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today that it has reached a worldwide milestone by surpassing 10,000 patients having received the Optimizer® system for the treatment of moderate HF. This milestone highlights the benefit and importance of this therapy in helping patients live a full life with HF.

“I noticed positive changes since the procedure, such as not feeling cold or numb, I could walk every day and everywhere, did my regular chores and shopping, and shared activities like swimming with my daughter,” said Tracey, who received her CCM® device in 2023. “I’m no longer huffing, puffing, or gasping for air,” said Joe, another HF patient who received his CCM device in 2022. “I’m reborn ─ a whole new person ─ no longer incapacitated. My life has changed so much that we’re considering taking a trip. And my wife is ecstatic because I have my life back, and we have ours again.”

“We are deeply motivated by the patients who benefit from CCM therapy. Their progress inspires us to continuously enhance our technology, aiming to improve the lives of those suffering from heart failure,” said David Prutchi, Chief Technology Officer for Impulse Dynamics, who has worked on the development of CCM therapy since its inception.

David had the opportunity to meet one of these patients, Raynita, who was implanted with an Optimizer device this year. Raynita saw immediate improvement after starting CCM therapy and gave the following remarks on the experience: “I feel like a different person. I can do things I haven’t done in years. I am attending my granddaughter’s college graduation!”

CCM is available in 44 countries, and the technology has continued to advance, based on the needs of patients and physicians. The latest generation of the proprietary CCM technology is the Optimizer Smart Mini, which offers a rechargeable battery with 20-year battery life and a smaller size designed to make the implant procedure faster and easier for patients and physicians.

“We are committed to ongoing innovation in this important therapy that has such a clear clinical need around the world,” said Jason Spees, CEO of Impulse Dynamics. “We are also getting closer to significantly impacting the implantable cardioverter defibrillator (ICD) market with successful enrollment in our INTEGRA-D clinical trial on the CCM-D® HF System, which is the first-of-its-kind technology, combining the lifesaving benefits of an ICD with HF symptom relief through CCM therapy in one device.”

The patients statements in this Press Release represent the testimonials of their individual outcomes and may not be typical for all patients.

About the Optimizer and CCM Therapy 

The Optimizer Smart Mini system delivers CCM therapy — the company’s proprietary technology — to the heart, providing an important treatment option for the millions of patients suffering from heart failure. CCM therapy is designed to significantly improve heart contraction, allowing more oxygen-rich blood to be pushed out through the body.[1] CCM therapy is indicated to improve 6-minute hall walk, quality of life, and functional status of NYHA Class III HF patients who remain symptomatic despite guideline directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

CCM is the brand name for cardiac contractility modulation—the non-excitatory electrical pulses delivered by the implantable Optimizer device to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during the absolute refractory period. In doing so, CCM helps the heart contract more forcibly. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, the results of which appeared in more than 100 articles from leading medical journals.

About Impulse Dynamics

Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in HF patients. CCM therapy is delivered through the Optimizer system, which includes an implantable pulse generator (IPG) implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 10,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, X (formerly Twitter), and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.


[1] European Journal of Heart Failure (2021) doi:10.1002/ejhf.2202

Attachment

Scott Way, Executive Vice President, General Counsel
Impulse Dynamics
856-434-7906
sway@impulsedynamics.com

Rohan More, Global Vice President, Marketing
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com

GlobeNewswire Distribution ID 9116301